Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients.
OBJECTIVE
Evaluate the serum vascular endothelial growth factor (VEGF) levels in the prognosis of lung cancer patients.


METHODS
Fifty-four serum samples were analyzed for VEGF concentrations (79.3% nonsmall cell lung cancer (NSCLC) and 20.7% small cell lung cancer).


RESULTS
Patients with serum VEGF-A levels higher than the mean of the patients studied (434.93 pg/mL) presented a shorter median survival time than those with lower levels (p =.04), as in patients with NSCLC tumors (p =.04) and in those with stages I-II (p <.05), and high serum VEGF-A levels.


CONCLUSIONS
Elevated VEGF serum levels have a negative prognostic impact on survival in NSCLC and early stages of lung cancer patients.
Carrillo-de Santa Pau
Enrique
E
Research Department, Ramón y Cajal Hospital, Madrid, Spain.
Carrillo Arias
Fernando
F
Caso Pelaez
Enrique
E
Muguruza Trueba
Ignacio
I
Sánchez Hernández
Ignacio
I
Muñoz Molina
Gemma María
GM
Moreno Balsalobre
Ramón
R
Sacristán López
Silvia
S
Gómez-Pinillos
Alejandro
A
Toledo Lobo
Maria del Val
Mdel V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D042461:Vascular Endothelial Growth Factor A